JP2001521374A - T細胞活性化および増殖を阻害するLO―CD2a抗体およびその用途 - Google Patents
T細胞活性化および増殖を阻害するLO―CD2a抗体およびその用途Info
- Publication number
- JP2001521374A JP2001521374A JP51067498A JP51067498A JP2001521374A JP 2001521374 A JP2001521374 A JP 2001521374A JP 51067498 A JP51067498 A JP 51067498A JP 51067498 A JP51067498 A JP 51067498A JP 2001521374 A JP2001521374 A JP 2001521374A
- Authority
- JP
- Japan
- Prior art keywords
- cd2a
- cells
- antibody
- days
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.LO−CD2aからのCDRを含む一つのヒト化抗体。 2.請求の範囲第1項記載のヒト化抗体であって、図31で示されるように、ヒ ト化抗体の軽鎖可変領域のフレームワークにラットLO−CD2a軽鎖可変領域 のアミノ酸9、12、41、42、50、51および82を更に含むことを特徴 とするヒト化抗体。 3.請求の範囲第2項記載のヒト化抗体であって、図33で示されるように、ヒ ト化抗体の軽鎖可変領域のフレームワークにラットLO−CD2a重鎖可変領域 のアミノ酸47、67、70、72、76、85、および87を更に含むことを 特徴とするヒト化抗体。 4.請求の範囲第1項記載のヒト化抗体であって、ここでヒト化抗体の軽鎖可変 領域が図31のアミノ酸配列を持つことを特徴とするヒト化抗体。 5.請求の範囲第4項記載のヒト化抗体であって、ここでヒト化抗体の重鎖可変 領域が図33のアミノ酸配列を持つことを特徴とするヒト化抗体。 6.患者にある免疫応答を阻害する一つの方法であって、 患者を請求の範囲第1項記載の抗体で処置することを含む方法。 7.患者にある移植片の拒絶を阻害する一つの方法であって、患者を請求の範囲 第1項記載の抗体で処置することを含むことを特徴とする方法。 8.ATTC HB 11423として寄託された細胞系によ り生産されたモノクローナル抗体と同じヒトリンパ球のエピトープあるいはその 部分と結合する一つのキメラ抗体、前記キメラ抗体はヒト化定常部および図29 で示されるようなアミノ酸配列を持つVL鎖ならびに図30で示されるようなア ミノ酸配列を持つVH鎖を持つことを特徴とするキメラ抗体。 9.患者にある免疫応答を阻害する一つの方法であって、患者を請求の範囲第8 項記載の抗体で処置することを含む方法。 10.患者にある移植片の拒絶を阻害する一つの方法であって、患者を請求の範 囲第8項記載の抗体で処置することを含む方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1996/013281 WO1998007444A1 (en) | 1996-08-16 | 1996-08-16 | LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001521374A true JP2001521374A (ja) | 2001-11-06 |
JP2001521374A5 JP2001521374A5 (ja) | 2004-09-24 |
Family
ID=22255617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51067498A Pending JP2001521374A (ja) | 1996-08-16 | 1996-08-16 | T細胞活性化および増殖を阻害するLO―CD2a抗体およびその用途 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0959899B9 (ja) |
JP (1) | JP2001521374A (ja) |
AT (1) | ATE432080T1 (ja) |
AU (1) | AU737602B2 (ja) |
CA (1) | CA2262546C (ja) |
DE (1) | DE69637943D1 (ja) |
DK (1) | DK0959899T3 (ja) |
ES (1) | ES2327980T3 (ja) |
HK (1) | HK1021318A1 (ja) |
PT (1) | PT959899E (ja) |
WO (1) | WO1998007444A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004002425A2 (en) * | 2002-06-28 | 2004-01-08 | Bio Transplant, Inc. | Process for promoting graft acceptance by depletion of hematopoietic stem cells |
JP2005536228A (ja) | 2002-08-21 | 2005-12-02 | レビビコア, インコーポレイテッド | 機能的α−1,3−ガラクトシルトランスフェラーゼのいかなる発現をも欠くブタ動物 |
CA2548080A1 (en) | 2003-11-05 | 2005-05-26 | University Of Pittsburgh | Porcine isogloboside 3 synthase protein, cdna, genomic organization, and regulatory region |
NZ549953A (en) | 2004-03-17 | 2010-11-26 | Revivicor Inc | Tissue products derived from animals lacking any expression of functional alpha 1,3 galactosyltransferase |
WO2021259927A2 (en) * | 2020-06-23 | 2021-12-30 | Zelarion Malta Limited | Anti-cd2 antibodies |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2700893A (en) | 1952-08-06 | 1955-02-01 | Teddy A Kudlacik | Balancing device |
US4798806A (en) * | 1980-01-08 | 1989-01-17 | Ortho Pharmaceutical Corporation | Compositions and methods using a monoclonal antibody to a human T cell antigen |
GB9125979D0 (en) * | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
CA2157500C (en) * | 1993-03-05 | 2005-08-16 | Herve Bazin | Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation |
CN113299700A (zh) | 2021-05-08 | 2021-08-24 | 武汉华星光电半导体显示技术有限公司 | 一种显示面板及其制备方法 |
-
1996
- 1996-08-16 ES ES96930529T patent/ES2327980T3/es not_active Expired - Lifetime
- 1996-08-16 AT AT96930529T patent/ATE432080T1/de active
- 1996-08-16 PT PT96930529T patent/PT959899E/pt unknown
- 1996-08-16 JP JP51067498A patent/JP2001521374A/ja active Pending
- 1996-08-16 DK DK96930529T patent/DK0959899T3/da active
- 1996-08-16 DE DE69637943T patent/DE69637943D1/de not_active Expired - Lifetime
- 1996-08-16 CA CA002262546A patent/CA2262546C/en not_active Expired - Fee Related
- 1996-08-16 AU AU69532/96A patent/AU737602B2/en not_active Ceased
- 1996-08-16 EP EP96930529A patent/EP0959899B9/en not_active Expired - Lifetime
- 1996-08-16 WO PCT/US1996/013281 patent/WO1998007444A1/en active Application Filing
-
2000
- 2000-01-11 HK HK00100173.9A patent/HK1021318A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2262546A1 (en) | 1998-02-26 |
DK0959899T3 (da) | 2009-09-07 |
EP0959899B9 (en) | 2009-10-21 |
PT959899E (pt) | 2009-08-28 |
HK1021318A1 (en) | 2000-06-09 |
EP0959899A1 (en) | 1999-12-01 |
WO1998007444A1 (en) | 1998-02-26 |
EP0959899B1 (en) | 2009-05-27 |
CA2262546C (en) | 2009-03-17 |
DE69637943D1 (de) | 2009-07-09 |
AU6953296A (en) | 1998-03-06 |
EP0959899A4 (en) | 2005-01-12 |
AU737602B2 (en) | 2001-08-23 |
ES2327980T3 (es) | 2009-11-05 |
ATE432080T1 (de) | 2009-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6180377B1 (en) | Humanized antibodies | |
US5817311A (en) | Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies | |
US5730979A (en) | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation | |
AU691811B2 (en) | Antibodies | |
US5951983A (en) | Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies | |
JP4195453B2 (ja) | T細胞の活性化と増殖を阻害するLO−CD2a抗体およびその用途 | |
JPH09512705A (ja) | E−セレクチンに対する抗体 | |
JPH05500312A (ja) | Cdr―移植された抗体 | |
JP2004000249A (ja) | 抗体の調製 | |
HU228845B1 (en) | Improved anti-ige antibodies and method of improving polypeptides | |
US6849258B1 (en) | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation | |
JP2001521374A (ja) | T細胞活性化および増殖を阻害するLO―CD2a抗体およびその用途 | |
US7592006B1 (en) | Composition comprising the LO-CD2a antibody | |
JP4808841B2 (ja) | T細胞活性化および増殖を阻害するLO−CD2a抗体およびその使用法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070507 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090421 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090819 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090820 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090821 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20091203 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20100225 |